Mission Produce reaffirms second-half fiscal 2026 Adjusted EBITDA outlook of $84 million-$88 million
Bitget2026/10/08 12:20Mission Produce reaffirmed fiscal 2026 second-half Adjusted EBITDA of $84 million-$88 million, including fourth-quarter Adjusted EBITDA of $52 million-$55 million. Second-half Mission Peru exportable volume outlook held at 120 million-130 million pounds, including 67 million-77 million pounds in the fourth quarter. Five-year targets call for mid-single-digit organic sales growth, roughly 300 basis points of margin expansion, cash conversion above 90% of Adjusted Net Income. Framework assumes high-single-digit organic Adjusted EBITDA growth over five years, supported by Calavo synergies and higher asset utilization. Annualized Calavo synergy target raised to more than $30 million from at least $25 million, with a small fiscal Q4 2026 contribution expected. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mission Produce Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001802974-26-000046), on October 08, 2026, and is solely responsible for the information contained therein.
- Mission Produce reaffirmed fiscal 2026 second-half Adjusted EBITDA of $84 million-$88 million, including fourth-quarter Adjusted EBITDA of $52 million-$55 million.
- Second-half Mission Peru exportable volume outlook held at 120 million-130 million pounds, including 67 million-77 million pounds in the fourth quarter.
- Five-year targets call for mid-single-digit organic sales growth, roughly 300 basis points of margin expansion, cash conversion above 90% of Adjusted Net Income.
- Framework assumes high-single-digit organic Adjusted EBITDA growth over five years, supported by Calavo synergies and higher asset utilization.
- Annualized Calavo synergy target raised to more than $30 million from at least $25 million, with a small fiscal Q4 2026 contribution expected.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
